---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-257259"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2022-10-04T23:59:59+00:00"
generated_at: "2026-06-23T05:37:44.409656+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Vir Biotechnology awarded up to $1B BARDA contract for influenza and pandemic preparedness

## Summary
- BARDA to invest ~$55M initially for VIR-2482 (influenza prophylactic mAb) development through Jan 2026.
- Phase 2 trial of VIR-2482 expected to start H2 2022; initial data anticipated mid-2023.
- Potential total investment up to $1B if BARDA exercises up to 12 options for additional candidates.
- Contract supports development of up to 10 emerging infectious disease or medical countermeasure candidates.

## SEC filing metadata
- accession: 0001193125-22-257259
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2022-10-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000119312522257259/0001193125-22-257259-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000119312522257259/d387221d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-257259
- JSON: https://secwatch.observer/filing/0001193125-22-257259.json
- Plain text: https://secwatch.observer/filing/0001193125-22-257259.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.